Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Abstract Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are ove...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Ileabett M Echevarría‐Vargas, Patricia I Reyes‐Uribe, Adam N Guterres, Xiangfan Yin, Andrew V Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei, Rajasekharan Somasundaram, Giorgos Karakousis, Wei Xu, Jennifer JD Morrissette, Yiling Lu, Gordon B Mills, Ryan J Sullivan, Miao Benchun, Dennie T Frederick, Genevieve Boland, Keith T Flaherty, Ashani T Weeraratna, Meenhard Herlyn, Ravi Amaravadi, Lynn M Schuchter, Christin E Burd, Andrew E Aplin, Xiaowei Xu, Jessie Villanueva
Format:	Artigo
Język:	Inglês
Wydane:	Springer Nature 2018-04-01
Seria:	EMBO Molecular Medicine
Hasła przedmiotowe:	BET combination therapy drug resistance melanoma mutant NRAS
Dostęp online:	https://doi.org/10.15252/emmm.201708446
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!